9）Pachman, DR, Qin R, Seisler DK, Smith EML, Beutler AS, Ta LE, et al. Clinical course of oxaliplatin-induced neuropathy: Results from the randomized Phase Ⅲ trial N08CB (alliance). J Clin Oncol 2015; 33(10): 3416-22.10）Brozou V, Vadalouca A, Zis P. Pain in platin-induced neuropathies: A systematic review and meta-analysis. Pain Ther 2018; 7(1): 105-19.11）Mahmoud ITB, Said AB, Berguiga S, Houij R, Cherif I, Handi A, et al. Incidence and risk factors associated with development of oxaliplatin-induced acute peripheral neuropathy in colorectal cancer patients. J Oncol Pharm Pract 2023; 29(2): 311-8.12）Hines RB, Schoborg C, Sumner T, Zhu X, Elgin EA, Zhang S. The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients. Support Care Cancer 2023; 31(7): 386.13）Aizawa F, Kajimoto H, Okabayashi A, Moriyama D, Yagi K, Takahashi S, et al. Statins ameliorate oxaliplatin- and paclitaxel-induced peripheral neuropathy via glutathione S-transferase. Neurochem Int 2024; 180: 105863.14）Schneider BP, Li L, Radovich M, Shen F, Miller KD, Flockhart DA, et al. Genome-wide association studies for taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res 2015; 21(22): 5082-91.15）Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol 2011; 12(12): 1151-61.文 献136 1）Hershman DL, Lacchetti C, Dworkin RH, Smith EML, Bleer J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors o f adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014; 32(18): 1941-67. 2）Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO Guideline Update. J Clin Oncol 2020; 38(28): 3325-48. 3）Tofthagen C. Surviving chemotherapy for colon cancer and living with the consequences. J Palliat Med 2010; 13(11): 1389-91. 4）Cheng F, Zhang R, Sun C, Ran Q, Zhang C, Shen C, et al. Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: Mechanisms, pharmacokinetics and strategies. Front Pharmacol 2023; 14: 1231401. 5）Zamami Y, Niimura T, Kawashiri T, Goda M, Naito Y, Fukushima K, et al. Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data. Biomed Pharmacother 2022; 148: 112744. 6）Bae EH, Greenwald MK, Schwartz AG. Chemotherapy-induced peripheral neuropathy: Mechanisms and therapeutic avenues. Neurotherapeutics 2021; 18(4): 2384-96. 7）Okamoto K, Nozawa H, Emoto S, Murono K, Sasaki K, Ishihara S. Does statin suppress oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer? A single-center observational study. Support Care Cancer 2023; 31(12): 660. 8）Ben Mahmoud IT, Ben Said A, Berguiga S, Houij R, Cherif I, Hamdi A, et al. Incidence and risk factors associated with development of oxalipatin-induced acute peripheral neuropathy in colorectal cancer patients. J Oncol Pharm Pract 2023; 29(2): 311-8.
元のページ ../index.html#154